Astec Lifesciences Intrinsic Value
Astec Lifesciences (ASTEC) median intrinsic value is ₹290.68 from 4 valuation models (range ₹178–₹291), vs current price ₹726.70 — -60.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Check Astec Lifesciences networth to track the company's total market size over time.
ASTEC Valuation Methods Summary — DCF, Graham Number & P/E
Astec Lifesciences intrinsic value across 4 models vs current price ₹726.70 — upside/downside and value range per method. For current market price and key ratios, visit Astec Lifesciences stock price NSE.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹177.73 | ₹159.96 - ₹195.50 | -75.5% | Book Value/Share: ₹177.73, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹234.18 | ₹210.76 - ₹257.60 | -67.8% | Revenue/Share: ₹292.73, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹290.68 | ₹261.61 - ₹319.75 | -60.0% | EBITDA: ₹48.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹290.68 | ₹232.54 - ₹348.82 | -60.0% | CF Growth: 5.0%, Discount: 15% |
ASTEC Intrinsic Value vs Market Price — All Valuation Models
Astec Lifesciences fair value range ₹178–₹291 vs current market price ₹726.70 across 4 valuation models. See Astec Lifesciences P/B valuation to compare market price against book value per share.
ASTEC Intrinsic Value Analysis — Undervalued or Overvalued?
Astec Lifesciences median intrinsic value ₹290.68, current price ₹726.70 — Trading Above Calculated Value by 60.0%, margin of safety -100.0%.
What is the intrinsic value of ASTEC?
Based on our comprehensive analysis using 4 different valuation methods, the estimated intrinsic value of Astec Lifesciences (ASTEC) is ₹290.68 (median value). With the current market price of ₹726.70, this represents a -60.0% variance from our estimated fair value.
The valuation range spans from ₹177.73 to ₹290.68, indicating ₹177.73 - ₹290.68.
Is ASTEC undervalued or overvalued?
Based on our multi-method analysis, Astec Lifesciences (ASTEC) appears to be trading above calculated value by approximately 60.0%.
ASTEC Financial Health — Key Ratios vs Industry Benchmarks
Astec Lifesciences financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 8.69 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | -8.2% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 6.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.68x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
ASTEC Cash Flow Quality — Operating & Free Cash Flow
Astec Lifesciences operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹-81 Cr | ₹-83 Cr | Negative Cash Flow | 3/10 |
| March 2025 | ₹-8 Cr | ₹-16 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹10 Cr | ₹-58 Cr | Positive Operating Cash Flow | 6/10 |
| March 2023 | ₹75 Cr | ₹19 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹24 Cr | ₹-28 Cr | Positive Operating Cash Flow | 6/10 |